Jonas Heilskov Graversen obtained his PhD in Molecular Biology from Aarhus University in 2000 in Molecular Biology. He continued as an innovation postdoc at Aarhus University. From 2003-2014 Jonas H. Graversen worked in the medical/biotech industry. Here he gained extensive experience in medical discovery, translational research, and planning transition from discovery into early development phase. He is co-founder of four biotech companies, focusing on development of biopharmaceuticals targeting immune cells in inflammatory diseases and cancer. He has several years of experience in managing drug discovery projects, both within academia and in biotech, and has served as daily manager of scientific teams in both academia and industry. In 2014 he joined Department of Molecular Medicine at the University of Southern Denmark.
His laboratory works extensively on receptor characterization and drug targeting using specific receptors as gateways and identification and development of novel biomarkers. Within liver diseases special focus is on development of non-invasive NASH biomarkers and understanding and modulating intercellular signalling for development novel treatment modalities for liver diseases, especially those related to obesity and inflammation.
